A reassessment of risks and benefits of dopamine agonists in Parkinson's disease

@article{Antonini2009ARO,
  title={A reassessment of risks and benefits of dopamine agonists in Parkinson's disease},
  author={Angelo Antonini and Eduardo Tolosa and Yoshikuni Mizuno and Mitsutoshi Yamamoto and Werner Poewe},
  journal={The Lancet Neurology},
  year={2009},
  volume={8},
  pages={929-937}
}
Role of Pramipexole in the Management of Parkinson’s Disease
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease and for the treatment of moderate-to-severe primary
Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
TLDR
The pharmacodynamic and cardiovascular effects of DAs on PD patients are reviewed, and results showed higher heart failure risk following use of pramipexole or cabergoline.
Early pharmacologic treatment in Parkinson's disease.
  • R. Hauser
  • Medicine, Psychology
    The American journal of managed care
  • 2010
TLDR
Physicians should also consider the early use of MAO-B inhibitors in light of their very good tolerability and the recent evidence suggesting long-term disease-modifying effects.
Levodopa in the treatment of Parkinson's disease: current status and new developments.
TLDR
Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor (DDCI), which reduces many treatment complications, extending its half-life and increasinglevodopa availability to the brain.
Prospects of successful treatment of Parkinson's disease using apomorphine
TLDR
This review provides historical background and summarises the structure, mechanism of action, pharmacodynamics, indications, contraindications, and side effects of subcutaneous apomorphine injections in the advanced stages of Parkinson's disease.
Pharmacological Treatment in Parkinson’s Disease
  • J. J. Lee
  • Biology, Psychology
    Journal of the Korean Neurological Association
  • 2019
TLDR
Evidence-based review of pharmacological treatment of Parkinson’s disease from early to advanced stages as well as management its unavoidable adverse reactions are provided.
Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson’s Disease
TLDR
Dopamine receptor agonists are indicated for the symptomatic treatment of early, moderate or advanced Parkinson’s disease as well as for the reduction of levodopa-related motor complications and other issues, including the efficacy of dopamine agonists for the treatment of non-motor symptoms, remain under evaluation.
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
TLDR
The issue of LD delivery as a critical factor for the drug’s propensity to induce motor complications is addressed and the available evidence regarding the use of LD to treat PD is summarized.
Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias
TLDR
The article highlights some interesting aspects of the clinical trials testing dopamine agonists monotherapy as a strategy that can reduce the risk of motor complications, and raises some concerns in terms of their early use in Parkinson’s disease treatment to prevent or delay dyskinesia.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 97 REFERENCES
Dopamine agonists in Parkinson’s disease
TLDR
Ropinirole and pramipexole have both demonstrated a reduction in the rate of loss of nigrostriatal innervation as determined by imaging in PD patients, when compared with levodopa.
The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinson’s Disease
TLDR
Improvements relative to baseline in average Unified Parkinson’s Disease Rating Scale (UPDRS) daily living activities and motor function sections, and in Clinical Global Impression severity of illness and physician-and patient-rated global improvement scores, were seen in both treatment groups, with maximal effects occurring within 2 years.
Dopamine agonist therapy in early Parkinson's disease.
TLDR
This meta-analysis confirms that motor complications are reduced with dopamine agonists compared to levodopa, but also establishes that other important side-effects are increased and symptom control is poorer with agonists.
Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review
TLDR
The authors conclude that selegiline has very mild symptomatic benefit with no evidence for neuroprotective benefit and levodopa provides superior motor benefit but is associated with a higher risk of dyskinesia.
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
TLDR
It is demonstrated that continuous lisuride infusion can be beneficial for patients with advanced Parkinson's disease and reverse established motor fluctuations and dyskinesia.
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
TLDR
It is indicated that pramipexole is safe and effective in the treatment of early Parkinson's disease and significantly reduced the severity of PD symptoms and signs compared with placebo.
Lisuride, a dopamine agonist in the treatment of early Parkinson's disease
  • U. Rinne
  • Medicine, Psychology
    Neurology
  • 1989
TLDR
It seems advisable that treatment should begin in the early phase of the disease with a dopamine agonist such as lisuride combined with a low dose of levodopa, during a 4-year follow-up.
Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review.
TLDR
This evidence-based review stressed that cabergoline, pramipexole, and ropinirole were shown to be superior to levodopa in delaying the motor fluctuations and dyskinesias in patients with early Parkinson’s disease.
...
1
2
3
4
5
...